NSAIDs and incident Alzheimer’s disease. The Rotterdam study
Abstract
Recent studies suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk for Alzheimer's disease (AD). We investigated the relation of NSAID use over a 10-year period and the risk for incident AD using a nested case-control design in the population-based Rotterdam Study. The study was performed in 306 subjects; 74 Alzheimer patients diagnosed according to NINCDS-ADRDRA criteria and 232 age and sex-matched controls. NSAID use was abstracted from general practitioners' medical records and expressed as cumulative prescription days. The relative risk for AD associated with long-term use (> or = 2 months) was 0.95 (95% CI: 0.46-1.99) as compared to nonusers, after controlling for possible confounders. In a separate examination, subjects who had more than 6 months of prescription days had a reduced relative risk for AD (RR = 0.74 (95% CI: 0.20-2.72). In an age-stratified analysis the effect in long-term users was evident in those aged 85 and under; 0.53 (95% CI: 0.15-1.77). All risk estimates were lower when the last 2 years of exposure were excluded from the analyses. Our point estimates in subjects younger than 85 years and in subjects using NSAIDs for 6 months or more are consistent with the hypothesis that long-term use of NSAIDs reduces the risk for AD. However, overall there was no association between NSAID use and the risk for incident AD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Retrospective studies demonstrate that sustained NSAID treatment during mid-life significantly decreases the risk of AD.
“Second, retrospective studies demonstrate that sustained NSAID treatment during mid-life significantly decreases the risk of AD (109, 110).”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [110]
Cites
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · see citing works
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · see citing works
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · see citing works
Self-citationIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · see citing works
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · see citing works
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W. K., Teter, B., Tran, T., Ubeda, O. J., Ashe, K. H., Frautschy, S. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 876 · see citing works
Dementia and Cognitive Impairment
Hugo, J., & Ganguli, M. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.001 · Cited by 916 · see citing works
SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling
Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.-F., Kwon, H., Yi, S., Mucke, L., & Gan, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509329200 · Cited by 740 · see citing works
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511 · see citing works
Cribbs, D. H., Berchtold, N. C., Perreau, V., Coleman, P. D., Rogers, J., Tenner, A. J., & Cotman, C. W. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-179 · Cited by 499 · see citing works
Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain
Kim, H., Park, S., Zhou, J.-L., Taglialatela, G., Chung, K., Coggeshall, R., & Chung, J.-M. (2004) · Pain · doi:10.1016/j.pain.2004.06.008 · Cited by 451 · see citing works
“…and neurodegeneration in the aging brain and in some neurodegenerative diseases are widely regarded as at least a partial consequence of ROS damage associated with increased levels of pro-inflammatory cytokines (Coyle and Puttfarcken, 1993; Götz et al., 1994; In’t Veld et al., 1998; Jenner, 1994).”
BackgroundYin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441 · see citing works
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 394 · see citing works
Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease
Ozben, T., & Ozben, S. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.001 · Cited by 381 · see citing works
Reduced incidence of AD with NSAID but not H2receptor antagonists
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K. M., Mayer, L. S., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 314 · see citing works
Judith Miklossy, A. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-90 · Cited by 356 · see citing works
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 260 · see citing works
Karran, E. H., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275 · see citing works
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270 · see citing works
Breteler, M. M. B. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06399.x · Cited by 234 · see citing works
Self-citationIbuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice
Lim, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00299-8 · Cited by 224 · see citing works
Martín-Moreno, A. M., Brera, B., Spuch, C., Carro, E., García‐García, L., Delgado, M., Pozo, M. A., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-8 · Cited by 246 · see citing works
Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists
Anthony, J. C., Breitner, J., Zandi, P., Meyer, M., Jurasová, I., Norton, M., & Stone, S. (2000) · Neurology · doi:10.1212/wnl.54.11.2066 · Cited by 222 · see citing works
The immunology of neurodegeneration
Czirr, E., & Wyss‐Coray, T. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58656 · Cited by 211 · see citing works
“Additional evidence linking systemic inflammation with neurodegeneration comes from epidemiological studies, which show that prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD (32) or PD (33) by as much as 50%.”
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of <i>APOE</i> and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204 · see citing works
Cao, Y., Chtarbanova, S., Petersen, A. J., & Ganetzky, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306220110 · Cited by 205 · see citing works
Arendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 188 · see citing works
Asanuma, M., Nishibayashi-Asanuma, S., Miyazaki, I., Kohno, M., & Ogawa, N. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00205.x · Cited by 190 · see citing works
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172 · see citing works
The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine.
Bergh, M. S., & Budsberg, S. (2005) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2005.tb02741.x · Cited by 161 · see citing works
Wardill, H. R., Mander, K. A., Sebille, Y. Z. A. V., Gibson, R. J., Logan, R. M., Bowen, J. M., & Sonis, S. T. (2016) · International Journal of Cancer · doi:10.1002/ijc.30252 · Cited by 176 · see citing works
Frodl, T., & Amico, F. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.013 · Cited by 147 · see citing works
Clinical aspects of inflammation in Alzheimer's disease
Rosenberg, P. B. (2005) · International Review of Psychiatry · doi:10.1080/02646830500382037 · Cited by 159 · see citing works
Lahiri, D. K., Maloney, B., Basha, R. M., Ge, Y. W., & Zawia, N. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362164 · Cited by 134 · see citing works
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129 · see citing works
The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease
Kokiko-Cochran, O. N., & Godbout, J. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00672 · Cited by 128 · see citing works
“Second, retrospective studies demonstrate that sustained NSAID treatment during mid-life significantly decreases the risk of AD (109, 110).”
BackgroundThe molecular basis of the prevention of Alzheimer's disease through healthy nutrition.
Steele, M. L., Stuchbury, G., & Münch, G. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.06.002 · Cited by 127 · see citing works
Rosenberger, T., Villacreses, N., Hovda, J., Bosetti, F., Weerasinghe, G. R., Wine, R. N., Harry, G., & Rapoport, S. I. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02246.x · Cited by 123 · see citing works
Putative role of neuronal 5-lipoxygenase in an aging brain
Manev, H., Uz, T., Sugaya, K., & Qu, T. (2000) · The FASEB Journal · doi:10.1096/fj.14.10.1464 · Cited by 113 · see citing works
“Recent clinical studies point to the beneficial effects of antiinflammatory treatments in Alzheimer’s patients (56, 57).”
Disease modifying therapy for AD?<sup>1</sup>
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117 · see citing works
Nonsteroidal anti‐inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease
Côté, S., Carmichael, P., Verreault, R., Lindsay, J., Lefèbvre, J., & Laurin, D. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.03.012 · Cited by 122 · see citing works
Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Arvanitakis, Z., Grodstein, F., Bienias, J. L., Schneider, J. A., Wilson, R. S., Kelly, J. F., Evans, D. A., & Bennett, D. A. (2008) · Neurology · doi:10.1212/01.wnl.0000313813.48505.86 · Cited by 116 · see citing works
Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition
Chakrabarty, P., Tianbai, L., Herring, A., Ceballos-Diaz, C., Das, P., & Golde, T. E. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-36 · Cited by 116 · see citing works
Hirohata, M., Ono, K., Naiki, H., & Yamada, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.07.004 · Cited by 131 · see citing works
Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence.
Zandi, P., & Breitner, J. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00297-4 · Cited by 112 · see citing works
Melah, K. E., Lu, S. Y.-F., Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150897 · Cited by 109 · see citing works
Hormetic effects of curcumin: What is the evidence?
Moghaddam, N. S. A., Oskouie, M. N., Butler, A., Petit, P., Barreto, G., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27880 · Cited by 103 · see citing works
The unsolved relationship of brain aging and late-onset Alzheimer disease
Kern, A., & Behl, C. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.016 · Cited by 106 · see citing works
Kukull, W. A., & Bowen, J. D. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00010-x · Cited by 106 · see citing works
Leoutsakos, J., Muthén, B., Breitner, J. C. S., & Lyketsos, C. G. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2723 · Cited by 105 · see citing works
Hewett, S. J., Bell, S. C., & Hewett, J. A. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.011 · Cited by 91 · see citing works
Apoptosis modulators in the therapy of neurodegenerative diseases
Deigner, H., Haberkorn, U., & Kinscherf, R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.4.747 · Cited by 93 · see citing works
“This study showed that overall there was no association between NSAID use and the incidence of AD [88].”
ResultThe pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases.
Mcgeer, E., Yasojima, K., Schwab, C., & McGeer, P. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00288-3 · Cited by 86 · see citing works
Cole, G. M., & Frautschy, S. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011991 · Cited by 84 · see citing works
Isoprenoids and Alzheimer's disease: A complex relationship
Cole, S. L., & Vassar, R. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.007 · Cited by 70 · see citing works
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study
Yip, A., Green, R., Huyck, M., Cupples, L., & Farrer, L. (2005) · BMC Geriatrics · doi:10.1186/1471-2318-5-2 · Cited by 78 · see citing works
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77 · see citing works
Moussa, N., & Dayoub, N. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101729 · Cited by 77 · see citing works
“For example, the Rotterdam Study reported that NSAIDs have effects on dementia risk and could reduce it (In ’t Veld et al., 1998).”
Neuroinflammation and Alzheimer Disease: Clinical and Therapeutic Implications
Eikelenboom, P., Rozemüller, A. J. M., Hoozemans, J. J. M., Veerhuis, R., & van Gool, W. A. (2000) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200000001-00009 · Cited by 78 · see citing works
The Chemistry of Neurodegeneration: Kinetic Data and Their Implications
Pavlin, M., Repič, M., Vianello, R., & Mavri, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9284-1 · Cited by 75 · see citing works
Klegeris, A., & McGeer, P. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.127 · Cited by 73 · see citing works
Philippens, I. H. C. H. M., Ormel, P. R., Baarends, G., Johansson, M., Remarque, E. J., & Doverskog, M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160673 · Cited by 79 · see citing works
Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?
Breitner, J., & Zandi, P. (2001) · New England Journal of Medicine · doi:10.1056/nejm200111223452110 · Cited by 72 · see citing works
Apetz, N., Münch, G. W., Govindaraghavan, S., & Gyengési, E. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917110635 · Cited by 72 · see citing works
“Further evidence was provided by several population-based cohorts and case-control studies that revealed a decreased risk for AD when comparing (long-term) NSAID-users to non-users [94-99].”
BackgroundDetrait, E., Danis, B., Lamberty, Y., & Foerch, P. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.04.001 · Cited by 69 · see citing works
“Elevation of TNF-a 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 Fifteen years ago, it was demonstrated that non-steroidal antiinflammatory drugs (NSAIDs) decreased the risk of developing Alzheimer’s disease (In ‘t Veld et al., 1998).”
BackgroundCornelius, C., Fastbom, J., Winblad, B. G., & Viitanen, M. H. (2004) · Neuroepidemiology · doi:10.1159/000075957 · Cited by 64 · see citing works
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66 · see citing works
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease
Tansey, M. G., & McAlpine (2008) · Journal of Inflammation Research · doi:10.2147/jir.s4397 · Cited by 54 · see citing works
New Anti-inflammatory Treatment Strategy in Alzheimer’s Disease
Sugaya, K., Uz, T., Kumar, V., & Manev, H. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.82.85 · Cited by 64 · see citing works
Dementia / Alzheimer's Disease
Lindsay, J., & Anderson, L. (2004) · BMC Women's Health · doi:10.1186/1472-6874-4-s1-s20 · Cited by 60 · see citing works
NSAIDs for the Chemoprevention of Alzheimer’s Disease
Szekely, C. A., Town, T., & Zandi, P. P. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_11 · Cited by 52 · see citing works
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 59 · see citing works
“Therefore, the protective effect of these NSAIDs, showed in epidemiological studies reporting lower rates of AD among people who had been taking these drugs for chronic treatment of inflammatory conditions [47,48], was then attributed to this γ-secretase modulating activity [41], and not to their COX inhibition.”
BackgroundThe Role of Eicosanoids in Alzheimer’s Disease
Biringer, R. G. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16142560 · Cited by 63 · see citing works
“Non-steroidal anti-inflammatory agents (NSAIDs) are known inhibitors of cyclooxygenases and there are numerous reports that show unequivocally that long term use of NSAIDs is associated with a reduction in the risk of developing AD [35,36].”
BackgroundTratamento farmacológico da doença de Alzheimer
Forlenza, O. V. (2005) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832005000300006 · Cited by 52 · see citing works
“Estudos epidemiológicos conduzidos no final década passada sugeriram que o uso prolongado de antiinflamatórios não-esteróides estaria associado a uma redução de na incidência de DA, porém não afetando o risco de demência vascular (in t’ Veld et al., 1998; 2001).”
BackgroundNeuroinflammation as a Potential Therapeutic Target in Alzheimer’s Disease
Liu, P., Wang, Y., Sun, Y., & Peng, G. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s357558 · Cited by 92 · see citing works
“The Rotterdam Study revealed a significantly decreased risk of AD among NSAIDs users of 2 or more years in duration (ie, 80% sparing).(16) The Multi-Institutional Research in Alzheimer’s Genetic Epidemiology (MIRAGE) study revealed a risk reduction of 36% and protective effects of NSAIDs exposure to be more pronounced…”
BackgroundClinical trials for preventing post stroke cognitive impairment
Ankolekar, S., Geeganage, C. M., Anderton, P., Hogg, C., & Bath, P. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.052 · Cited by 56 · see citing works
“Further, the effect of interventions may take time to develop as seen with antihypertensives in preventing stroke, and with NSAIDS and dementia [52].”
Sparing of age-related macular degeneration in rheumatoid arthritis
McGeer, P. L., & Sibley, J. T. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.003 · Cited by 51 · see citing works
Jonker, C., Comijs, H., & Smit, J. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00188-4 · Cited by 50 · see citing works
Veld, B. A. I. (2002) · Epidemiologic Reviews · doi:10.1093/epirev/mxf001 · Cited by 56 · see citing works
“…1.59), NSAID + aspirin Brooks et al., 1998 (43) NSAID (current use), aspirin Interview Prospective cohort study Community (8.4% = 53) Community NS Cornelius et al., 1998 (51) NSAID taken regularly Interview Prospective populationbased cohort study Cohort (n = 110) Cohort 0.8 (0.4, 1.9) in ’t…”
InfluentialSelf-citationwu, S. O. S.-Z., Basile, A., & Barger, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507781077241 · Cited by 46 · see citing works
Klaver, D. W., Wilce, M. C. J., Cui, H., Hung, A. C., Gasperini, R., Foa, L. C., & Small, D. H. (2010) · Biological Chemistry · doi:10.1515/bc.2010.089 · Cited by 41 · see citing works
Klegeris, A., & McGeer, P. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7517 · Cited by 44 · see citing works
Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study.
Beiderbeck-Noll, A. B., Sturkenboom, M., van der Linden, P. D., Herings, R. M., Hofman, A., Coebergh, J., Leufkens, H., & Stricker, B. H. C. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00157-0 · Cited by 42
Self-citationLee, H., Villacreses, N., Rapoport, S., & Rosenberger, T. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02786.x · Cited by 41 · see citing works
Gahtan, E., & Overmier, J. (2001) · Physiology and Behavior · doi:10.1016/s0031-9384(01)00471-1 · Cited by 41 · see citing works
Petegnief, V., Saura, J., DeGregorio‐Rocasolano, N., & Paul, S. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00046-x · Cited by 39 · see citing works
Lowering the risk of Alzheimer's disease: Evidence‐based practices emerge from new research
Jedrziewski, M., Lee, V. M., & Trojanowski, J. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.09.007 · Cited by 37 · see citing works
Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls
Cisbani, G., & Rivest, S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01083-4 · Cited by 43 · see citing works
“between use of NSAIDs and risk for incident of AD [53].”
BackgroundTreatments for Alzheimer Disease
Potyk, D. K. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166671.86815.c1 · Cited by 37 · see citing works
The role of microglia in Alzheimer’s disease: friend or foe?
Schenk, D., & Yednock, T. A. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00034-9 · Cited by 32 · see citing works
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45 · see citing works
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
Golde, T. E., Streit, W. J., & Chakrabarty, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt178 · Cited by 38 · see citing works
Watterson, D., Mirzoeva, S., Guo, L.-Y., Whyte, A., Bourguignon, J., Hibert, M., Haiech, J., & Eldik, L. V. V. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00053-5 · Cited by 33 · see citing works
Scorer, C. A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02042-6 · Cited by 32 · see citing works
Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer’s disease
Babiloni, C., Frisoni, G. B., Percio, C. D., Zanetti, O. O., Bonomini, C., Cassetta, E., Pasqualetti, P., Miniussi, C., Rosas, M. D., Valenzano, A. A., et al. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.02.005 · Cited by 33 · see citing works
Asanuma, M., & Miyazaki, I. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1313 · Cited by 28 · see citing works
Du, Y.-S., Chen, X., Wei, X.-L., Bales, K., Berg, D., Paul, S., Farlow, M., Maloney, B., Ge, Y.-W., & Lahiri, D. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.02.001 · Cited by 28 · see citing works
Inflammation and aging: Can endocannabinoids help?
Marchalant, Y., Brothers, H. M., & Wenk, G. L. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.004 · Cited by 29 · see citing works
“Long term use of anti-inflammatory drugs has been hypothesized to counteract with these processes and thus protect against the disease; epidemiological evidence supports the long term use of NSAIDs to reduce the prevalence of AD (Andersen et al., 1995; In’T Veld et al., 1998).”
BackgroundWolfson, C., Perrault, A., Moride, Y., Esdaile, J., Abenhaim, L., & Momoli, F. (2002) · Neuroepidemiology · doi:10.1159/000048621 · Cited by 27 · see citing works
- Authors
- In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C.
- Affiliations
- Erasmus MC (NL)
- Utrecht University (NL)
- Dutch Health Care Inspectorate (NL)
- Corresponding author
- Launer, L.J
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 1998-11
- Volume
- 19
- Issue
- 6
- Pages
- 607-611
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W1965756304
- Cited by
- 145
- References
- 0
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 1 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 6 · 2015: 1 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Rivm (National Institute for Public Health and the Environment) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
- Keywords
- nonsteroidal anti-inflammatory drugs, Alzheimer's disease, long-term NSAID use, Rotterdam Study
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Male, Middle Aged, Risk, Logistic Models, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
